Samsara Bio Capital, LLC Eliem Therapeutics, Inc. Call Options Transaction History
Samsara Bio Capital, LLC
- $326 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ELYM
# of Institutions
76Shares Held
51MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$6.19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
-
Bank Of America Corp Charlotte, NC1.03MShares$4.25 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...